| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2017-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102403660-B1 |
| titleOfInvention |
Diagnosis of Immune Activation Using CLEVER-1, TNF-α and HLA-DR Binding Agents |
| abstract |
Agents capable of binding CLEVER-1 in an individual can be used to activate macrophages to convert their phenotype from M2 macrophages to M1 macrophages. The present invention relates to methods of using the ability of macrophages to transform their phenotype. In one aspect, the present invention relates to a method for evaluating the efficacy of anti-CLEVER-1 therapy by monitoring the modulation of M2 macrophages to M1 macrophages when an agent capable of binding to CLEVER-1 is administered to a patient As such, increased TNF-alpha secretion or HLA-DR expression is indicative of modulation of M2 macrophages to M1 macrophages. |
| priorityDate |
2016-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |